Suzhou first people's hospital
Suzhou, Jiangsu, China
NCT Number: NCT05871905
[14 C] Mass balance clinical trial of TY-9591 in healthy Chinese subjects
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 1
Suzhou, Jiangsu, China
This is a single-center, non-randomized, one-arm, open trial in healthy adult subjects. The study population is male healthy subjects. The trial consisted of a screening period, a trial period and a follow-up period. A total of 6-10 healthy Chinese adult male subjects were planned to be enrolled and divided into groups according to specific conditions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
2.Subjects were sterile themselves, or voluntarily took highly effective non-drug contraception or abstained from sex completely from the beginning of self-medication to 1 year after administration.
3.Volunteer to participate and sign informed consent, be able to communicate well with the investigator and complete the investigator in accordance with the study regulations.
Exclusion criteria
2.Abnormal ophthalmic examination (intraocular pressure, slit lamp, fundus film) with clinical significance.
3.Test positive for either hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antigen/antibody, or syphilis antibo.
4.Those who smoked more than 5 cigarettes a day or habitually used nicotine products in the 3 months before screening, or were unable to abstain during the trial.
5.A history of severe diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal system, respiratory system, metabolism and bone system, or any other disease or physiological condition that may affect the results of the study.
6.Who participated in any drug clinical trial as a subject within 3 months prior to the administration of this trial.
7.Those who had taken any prescription, over-the-counter, herbal and health products in the 14 days prior to screening.
8.Those who cannot tolerate venous puncture blood collection or fainting blood or fainting needle.
9.Those who have special dietary requirements and fail to follow the diets and regulations provided.
10.The investigator considers it inappropriate to participate in clinical trials or is otherwise unable to complete the study.
C14 TY-9591
Other names: C14 TY-9591
Time frame: After oral administration of 14C TY-9591, the radiometabolite profiles of plasma, urine and stool were obtained to identify the major metabolites
The total radioactivity in excreta after oral administration of 14C TY-9591
Time frame: 8m
To observe the safety of 14C TY-9591 in healthy subjects after a single dose
TYK Medicines, Inc
Industry
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Adult Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07422298
Healthy Volunteers
San Antonio, Texas, United States
View Trial DetailsNCT07215299
Healthy Volunteers
Bloomington, Indiana, United States
View Trial DetailsNCT03113903
Anxiety Disorders, Behavior
Clermont-Ferrand, France
View Trial DetailsNCT07742137
Aging, Behavior
Seville, Spain
View Trial Details